A federal appeals court on Friday reinstated a 2017 jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million (182 million pounds) for infringing a patent for its blood pressure drug Coreg.
The 2-1 decision was issued by the U.S. Federal Circuit Court of Appeals in Washington, D.C.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.